Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build Kenya flag

Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions

: Kenya OCM Protocol Markers Code System

Active as of 2026-06-04

Raw xml | Download


<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="ocm-protocol-markers-cs"/>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem ocm-protocol-markers-cs</b></p><a name="ocm-protocol-markers-cs"> </a><a name="hcocm-protocol-markers-cs"> </a><p>This case-sensitive code system <code>https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">HER2-POSITIVE<a name="ocm-protocol-markers-cs-HER2-POSITIVE"> </a></td><td>HER2 Positive</td><td>HER2/neu overexpression or amplification detected.</td></tr><tr><td style="white-space:nowrap">HER2-NEGATIVE<a name="ocm-protocol-markers-cs-HER2-NEGATIVE"> </a></td><td>HER2 Negative</td><td>No HER2/neu overexpression or amplification.</td></tr><tr><td style="white-space:nowrap">ER-POSITIVE<a name="ocm-protocol-markers-cs-ER-POSITIVE"> </a></td><td>ER Positive</td><td>Oestrogen receptor positive.</td></tr><tr><td style="white-space:nowrap">ER-NEGATIVE<a name="ocm-protocol-markers-cs-ER-NEGATIVE"> </a></td><td>ER Negative</td><td>Oestrogen receptor negative.</td></tr><tr><td style="white-space:nowrap">PR-POSITIVE<a name="ocm-protocol-markers-cs-PR-POSITIVE"> </a></td><td>PR Positive</td><td>Progesterone receptor positive.</td></tr><tr><td style="white-space:nowrap">PR-NEGATIVE<a name="ocm-protocol-markers-cs-PR-NEGATIVE"> </a></td><td>PR Negative</td><td>Progesterone receptor negative.</td></tr><tr><td style="white-space:nowrap">TRIPLE-NEGATIVE<a name="ocm-protocol-markers-cs-TRIPLE-NEGATIVE"> </a></td><td>Triple Negative</td><td>ER-, PR-, HER2- breast cancer.</td></tr><tr><td style="white-space:nowrap">KRAS-MUTANT<a name="ocm-protocol-markers-cs-KRAS-MUTANT"> </a></td><td>KRAS Mutant</td><td>KRAS mutation detected.</td></tr><tr><td style="white-space:nowrap">KRAS-WILD-TYPE<a name="ocm-protocol-markers-cs-KRAS-WILD-TYPE"> </a></td><td>KRAS Wild-type</td><td>No KRAS mutation.</td></tr><tr><td style="white-space:nowrap">BRAF-V600E<a name="ocm-protocol-markers-cs-BRAF-V600E"> </a></td><td>BRAF V600E Mutant</td><td>BRAF V600E mutation detected.</td></tr><tr><td style="white-space:nowrap">PD-L1-POSITIVE<a name="ocm-protocol-markers-cs-PD-L1-POSITIVE"> </a></td><td>PD-L1 Positive</td><td>PD-L1 expression ≥1%.</td></tr><tr><td style="white-space:nowrap">PD-L1-NEGATIVE<a name="ocm-protocol-markers-cs-PD-L1-NEGATIVE"> </a></td><td>PD-L1 Negative</td><td>PD-L1 expression &lt;1%.</td></tr><tr><td style="white-space:nowrap">MSI-HIGH<a name="ocm-protocol-markers-cs-MSI-HIGH"> </a></td><td>MSI-High</td><td>Microsatellite instability high.</td></tr><tr><td style="white-space:nowrap">MSI-LOW<a name="ocm-protocol-markers-cs-MSI-LOW"> </a></td><td>MSI-Low / MSS</td><td>Microsatellite instability low or stable.</td></tr><tr><td style="white-space:nowrap">EGFR-MUTANT<a name="ocm-protocol-markers-cs-EGFR-MUTANT"> </a></td><td>EGFR Mutant</td><td>EGFR mutation detected.</td></tr><tr><td style="white-space:nowrap">ALK-POSITIVE<a name="ocm-protocol-markers-cs-ALK-POSITIVE"> </a></td><td>ALK Positive</td><td>ALK rearrangement detected.</td></tr><tr><td style="white-space:nowrap">NOT-TESTED<a name="ocm-protocol-markers-cs-NOT-TESTED"> </a></td><td>Not Tested</td><td>Biomarker testing not performed.</td></tr></table></div>
  </text>
  <url
       value="https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs"/>
  <version value="0.1.0"/>
  <name value="OCMProtocolMarkersCS"/>
  <title value="Kenya OCM Protocol Markers Code System"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2026-06-04T14:49:30+00:00"/>
  <publisher value="Digital Health Agency (DHA), Kenya"/>
  <contact>
    <name value="Digital Health Agency (DHA), Kenya"/>
    <telecom>
      <system value="url"/>
      <value value="https://dha.go.ke"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="info@dha.go.ke"/>
    </telecom>
  </contact>
  <contact>
    <name value="Digital Health Agency Kenya – FHIR Team"/>
    <telecom>
      <system value="email"/>
      <value value="info@dha.go.ke"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="url"/>
      <value value="https://dha.go.ke"/>
      <use value="work"/>
    </telecom>
  </contact>
  <description
               value="Biomarker and molecular marker codes used for treatment protocol selection."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="KE"/>
      <display value="Kenya"/>
    </coding>
  </jurisdiction>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="17"/>
  <concept>
    <code value="HER2-POSITIVE"/>
    <display value="HER2 Positive"/>
    <definition value="HER2/neu overexpression or amplification detected."/>
  </concept>
  <concept>
    <code value="HER2-NEGATIVE"/>
    <display value="HER2 Negative"/>
    <definition value="No HER2/neu overexpression or amplification."/>
  </concept>
  <concept>
    <code value="ER-POSITIVE"/>
    <display value="ER Positive"/>
    <definition value="Oestrogen receptor positive."/>
  </concept>
  <concept>
    <code value="ER-NEGATIVE"/>
    <display value="ER Negative"/>
    <definition value="Oestrogen receptor negative."/>
  </concept>
  <concept>
    <code value="PR-POSITIVE"/>
    <display value="PR Positive"/>
    <definition value="Progesterone receptor positive."/>
  </concept>
  <concept>
    <code value="PR-NEGATIVE"/>
    <display value="PR Negative"/>
    <definition value="Progesterone receptor negative."/>
  </concept>
  <concept>
    <code value="TRIPLE-NEGATIVE"/>
    <display value="Triple Negative"/>
    <definition value="ER-, PR-, HER2- breast cancer."/>
  </concept>
  <concept>
    <code value="KRAS-MUTANT"/>
    <display value="KRAS Mutant"/>
    <definition value="KRAS mutation detected."/>
  </concept>
  <concept>
    <code value="KRAS-WILD-TYPE"/>
    <display value="KRAS Wild-type"/>
    <definition value="No KRAS mutation."/>
  </concept>
  <concept>
    <code value="BRAF-V600E"/>
    <display value="BRAF V600E Mutant"/>
    <definition value="BRAF V600E mutation detected."/>
  </concept>
  <concept>
    <code value="PD-L1-POSITIVE"/>
    <display value="PD-L1 Positive"/>
    <definition value="PD-L1 expression ≥1%."/>
  </concept>
  <concept>
    <code value="PD-L1-NEGATIVE"/>
    <display value="PD-L1 Negative"/>
    <definition value="PD-L1 expression &lt;1%."/>
  </concept>
  <concept>
    <code value="MSI-HIGH"/>
    <display value="MSI-High"/>
    <definition value="Microsatellite instability high."/>
  </concept>
  <concept>
    <code value="MSI-LOW"/>
    <display value="MSI-Low / MSS"/>
    <definition value="Microsatellite instability low or stable."/>
  </concept>
  <concept>
    <code value="EGFR-MUTANT"/>
    <display value="EGFR Mutant"/>
    <definition value="EGFR mutation detected."/>
  </concept>
  <concept>
    <code value="ALK-POSITIVE"/>
    <display value="ALK Positive"/>
    <definition value="ALK rearrangement detected."/>
  </concept>
  <concept>
    <code value="NOT-TESTED"/>
    <display value="Not Tested"/>
    <definition value="Biomarker testing not performed."/>
  </concept>
</CodeSystem>